

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

| | |
|-------------------------------|--|
| Drug | teriflunomide |
| Brand Name | Aubagio™ |
| Dosage Form | 14 mg tablet |
| Manufacturer | Genzyme Canada Inc. |
| Submission Review | New Submission |
| Use Reviewed | Relapsing-Remitting Multiple Sclerosis (RRMS) |
| Common Drug Review (CDR) | Yes. CDR recommended not to list at the submitted price. Visit CDR website for more details: www.cadth.ca/media/cdr/complete/SR0350_complete_Aubagio_Jun-19-14.pdf |
| Drug Benefit Council (DBC) | DBC met on August 18, 2014. DBC considered various inputs including: final review completed by the Common Drug Review (CDR) on June 18, 2014, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from 12 patients, 1 caregiver, and 1 patient group; Clinical Practice Reviews from one specialist and one general physician, Manufacturer comments on the CDEC Final Recommendation, as well as a Budget Impact Assessment. |
| Drug Coverage Decision | Limited Coverage benefit. www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/teriflunomide.html |
| Date | December 9, 2014 |
| Reason(s) | Drug coverage decision is generally consistent with the DBC recommendation. DBC recommended that teriflunomide be listed as a second-line option based on cost, but the Ministry was able to address cost concerns. <ul style="list-style-type: none"> The drug was similar to interferon beta-1a and better than placebo with respect to efficacy. The drug was not superior to other available treatments for RRMS. Based on economic considerations and the negotiated product price, the drug was cost effective and offered value for money. |
| Other Information | None |

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, visit
www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf.

For more information about the Medical Beneficiary and Pharmaceutical Services Division
and the PharmaCare program, visit www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.